Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$2.13
At close: May 23 EDT
$2.15
0.020.94%
Pre-Market: 4:39 AM EDT
Comments
Loading...
CytomX Therapeutics Analyst Ratings and Price Targets | NASDAQ:CTMX | Benzinga
CytomX Therapeutics Inc has a consensus price target of $5.39 based on the ratings of 10 analysts. The high is $8 issued by Wedbush on May 9, 2024. The low is $2 issued by Mizuho on March 28, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Piper Sandler, and HC Wainwright & Co. on May 20, 2025, May 15, 2025, and May 15, 2025, respectively. With an average price target of $5 between HC Wainwright & Co., Piper Sandler, and HC Wainwright & Co., there's an implied 132.56% upside for CytomX Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Piper Sandler
BMO Capital
Wedbush
Jefferies
1calculated from analyst ratings
Analyst Ratings for CytomX Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/20/2025 | Buy Now | 132.56% | HC Wainwright & Co. | Mitchell Kapoor45% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2025 | Buy Now | 132.56% | Piper Sandler | Joseph Catanzaro44% | $2.5 → $5 | Maintains | Overweight | Get Alert |
| 05/15/2025 | Buy Now | 132.56% | HC Wainwright & Co. | Mitchell Kapoor45% | $5 → $5 | Upgrade | Neutral → Buy | Get Alert |
| 04/14/2025 | Buy Now | 16.28% | Piper Sandler | Joseph Catanzaro44% | $3.25 → $2.5 | Maintains | Overweight | Get Alert |
| 03/07/2025 | Buy Now | — | HC Wainwright & Co. | Mitchell Kapoor45% | — | Reiterates | Neutral → Neutral | Get Alert |
| 01/07/2025 | Buy Now | — | HC Wainwright & Co. | Mitchell Kapoor45% | — | Reiterates | Neutral → Neutral | Get Alert |
| 11/11/2024 | Buy Now | — | HC Wainwright & Co. | Mitchell Kapoor45% | — | Reiterates | → Neutral | Get Alert |
| 09/13/2024 | Buy Now | — | HC Wainwright & Co. | Mitchell Kapoor45% | — | Reiterates | → Neutral | Get Alert |
| 08/22/2024 | Buy Now | — | HC Wainwright & Co. | Mitchell Kapoor45% | — | Reiterates | → Neutral | Get Alert |
| 06/27/2024 | Buy Now | — | HC Wainwright & Co. | Mitchell Kapoor45% | — | Reiterates | → Neutral | Get Alert |
| 05/28/2024 | Buy Now | 62.79% | Piper Sandler | Joseph Catanzaro44% | $2.25 → $3.5 | Upgrade | Neutral → Overweight | Get Alert |
| 05/09/2024 | Buy Now | 66.98% | BMO Capital | Etzer Darout44% | $3.25 → $3.59 | Maintains | Market Perform | Get Alert |
| 05/09/2024 | Buy Now | — | HC Wainwright & Co. | Mitchell Kapoor45% | — | Reiterates | → Neutral | Get Alert |
| 05/09/2024 | Buy Now | 272.09% | Wedbush | Robert Driscoll44% | $3 → $8 | Upgrade | Neutral → Outperform | Get Alert |
| 05/06/2024 | Buy Now | 272.09% | Jefferies | Roger Song35% | $2.5 → $8 | Upgrade | Hold → Buy | Get Alert |
| 05/01/2024 | Buy Now | 51.16% | BMO Capital | Etzer Darout44% | $3.25 → $3.25 | Reiterates | Market Perform → Market Perform | Get Alert |
| 04/22/2024 | Buy Now | — | JP Morgan | Anupam Rama57% | — | Upgrade | Underweight → Neutral | Get Alert |
| 03/12/2024 | Buy Now | 39.53% | Wedbush | Robert Driscoll44% | $3 → $3 | Reiterates | Neutral → Neutral | Get Alert |
| 03/12/2024 | Buy Now | 51.16% | BMO Capital | Etzer Darout44% | $3.3 → $3.25 | Maintains | Market Perform | Get Alert |
| 11/09/2023 | Buy Now | 39.53% | Wedbush | Robert Driscoll44% | $2 → $3 | Maintains | Neutral | Get Alert |
| 11/08/2023 | Buy Now | 39.53% | Wedbush | Robert Driscoll44% | $2 → $3 | Upgrade | Neutral → Outperform | Get Alert |
| 08/09/2023 | Buy Now | 48.37% | BMO Capital | Etzer Darout44% | $3.15 → $3.19 | Maintains | Market Perform | Get Alert |
| 03/28/2023 | Buy Now | -6.98% | Mizuho | Mara Goldstein56% | $4 → $2 | Maintains | Neutral | Get Alert |
| 01/06/2023 | Buy Now | 48.84% | BMO Capital | Etzer Darout44% | $2.6 → $3.2 | Maintains | Market Perform | Get Alert |
| 11/14/2022 | Buy Now | 20.93% | BMO Capital | Etzer Darout44% | $3 → $2.6 | Downgrade | Outperform → Market Perform | Get Alert |
| 11/10/2022 | Buy Now | — | JP Morgan | Anupam Rama57% | — | Downgrade | Overweight → Underweight | Get Alert |
| 07/11/2022 | Buy Now | — | Cowen & Co. | Boris Peaker48% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 07/11/2022 | Buy Now | — | HC Wainwright & Co. | Mitchell Kapoor45% | — | Downgrade | Buy → Neutral | Get Alert |
| 07/07/2022 | Buy Now | -6.98% | Jefferies | Roger Song35% | $12 → $2 | Downgrade | Buy → Hold | Get Alert |
| 07/07/2022 | Buy Now | 39.53% | BMO Capital | Etzer Darout44% | $9 → $3 | Maintains | Outperform | Get Alert |
| 07/07/2022 | Buy Now | 272.09% | BTIG | Kaveri Pohlman25% | $16 → $8 | Maintains | Buy | Get Alert |
| 07/07/2022 | Buy Now | -6.98% | Wedbush | Robert Driscoll44% | $6 → $2 | Downgrade | Outperform → Neutral | Get Alert |
| 07/07/2022 | Buy Now | 62.79% | Barclays | Peter Lawson42% | $7 → $3.5 | Maintains | Overweight | Get Alert |
| 07/07/2022 | Buy Now | 86.05% | Mizuho | Mara Goldstein56% | $16 → $4 | Downgrade | Buy → Neutral | Get Alert |
| 07/07/2022 | Buy Now | -30.23% | Piper Sandler | Joseph Catanzaro44% | $10 → $1.5 | Downgrade | Overweight → Neutral | Get Alert |
| 06/24/2022 | Buy Now | 318.6% | BMO Capital | Etzer Darout44% | → $9 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for CytomX Therapeutics (CTMX) stock?
The latest price target for CytomX Therapeutics (NASDAQ:CTMX) was reported by HC Wainwright & Co. on May 20, 2025. The analyst firm set a price target for $5.00 expecting CTMX to rise to within 12 months (a possible 132.56% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for CytomX Therapeutics (CTMX)?
The latest analyst rating for CytomX Therapeutics (NASDAQ:CTMX) was provided by HC Wainwright & Co., and CytomX Therapeutics reiterated their buy rating.
When was the last upgrade for CytomX Therapeutics (CTMX)?
The last upgrade for CytomX Therapeutics Inc happened on May 15, 2025 when HC Wainwright & Co. raised their price target to $5. HC Wainwright & Co. previously had a neutral for CytomX Therapeutics Inc.
When was the last downgrade for CytomX Therapeutics (CTMX)?
The last downgrade for CytomX Therapeutics Inc happened on November 14, 2022 when BMO Capital changed their price target from $3 to $2.6 for CytomX Therapeutics Inc.
When is the next analyst rating going to be posted or updated for CytomX Therapeutics (CTMX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CytomX Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CytomX Therapeutics was filed on May 20, 2025 so you should expect the next rating to be made available sometime around May 20, 2026.
Is the Analyst Rating CytomX Therapeutics (CTMX) correct?
While ratings are subjective and will change, the latest CytomX Therapeutics (CTMX) rating was a reiterated with a price target of $5.00 to $5.00. The current price CytomX Therapeutics (CTMX) is trading at is $2.15, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
